Zepbound vs Wegovy: Which Weight Loss Drug Is Actually Better for You?
Here's the bottom line from clinical trials: Zepbound typically produces about 5-7 percentage points more weight loss than Wegovy over a year to 18 months. But Wegovy has years of rigorous data showing it reduces heart attacks, strokes, and cardiovascular deaths. Zepbound's heart protection data is still being gathered, with major trial results expected soon.
How Do These Drugs Actually Work?
Both medications mimic hormones called incretins that your gut naturally releases after eating. They enhance insulin production, slow stomach emptying, and reduce appetite.
The key difference is in their mechanism:
- Wegovy (semaglutide) targets one hormone receptor: GLP-1
- Zepbound (tirzepatide) targets two hormone receptors: both GLP-1 and GIP
This "dual action" approach appears to be why Zepbound produces greater weight loss, though researchers are still working out exactly why targeting both receptors makes such a difference.
How Much More Weight Will You Actually Lose?
The most direct answer comes from SURMOUNT-5, a 72-week head-to-head trial in adults with obesity but no diabetes. People on maximum doses of tirzepatide (Zepbound) lost an average of 20.2% of their body weight. Those on semaglutide (Wegovy) lost 13.7%. That's roughly 6.5 percentage points more with Zepbound.
To put this in practical terms: if you weigh 220 pounds, Wegovy might get you to around 190 pounds. Zepbound could get you closer to 176 pounds.
Other studies back this up. A network meta-analysis of obesity trials found about a 6-7 percentage point advantage for tirzepatide. Real-world data from US patients showed tirzepatide produced 2-7 percentage points more weight loss than semaglutide over 3-12 months. The gap varies depending on dosing, how long people stay on the medication, and individual responses.
What About Heart Attacks and Strokes?
This is where Wegovy has a substantial advantage in the evidence.
Semaglutide (Wegovy) has been studied in multiple large, long-term cardiovascular outcome trials. The SELECT trial, which followed obese patients with heart disease but no diabetes for about 40 months, showed semaglutide reduced major cardiovascular events (heart attacks, strokes, and cardiovascular deaths) by 20% compared to placebo. Additional analyses showed benefits for heart failure, all-cause death, and kidney outcomes.
For people with type 2 diabetes, combined data from the SUSTAIN-6 and PIONEER-6 trials showed about a 24% reduction in major cardiovascular events.
Tirzepatide's cardiovascular story is less complete. A meta-analysis of its diabetes trials showed it doesn't increase cardiovascular risk (reassuring for safety), and there are hints it might reduce events. Some observational studies suggest benefits. But the definitive proof is still coming.
Two major trials are underway: SURPASS-CVOT is comparing tirzepatide to another diabetes drug in people with type 2 diabetes and heart disease. SURMOUNT-MMO is testing whether tirzepatide reduces heart attacks, strokes, heart failure events, and death in 15,000 obese people without diabetes. Both are event-driven trials, meaning results won't come until enough cardiovascular events have occurred, likely in the latter half of the 2020s.
What Side Effects Should You Expect?
Both drugs cause similar gastrointestinal problems, especially when you're starting or increasing your dose:
- Nausea
- Vomiting
- Diarrhea
- Constipation
These side effects cause some people to stop treatment entirely. Both drugs also carry warnings for gallbladder disease, pancreatitis, kidney issues, and potential thyroid concerns, though these serious effects are uncommon.
There are some potential differences emerging from pharmacovigilance data. Reviews suggest tirzepatide may have similar or fewer overall reported adverse events compared to semaglutide. Semaglutide has shown stronger signals in adverse event databases for gallbladder problems and some unusual events like hair loss.
Both drugs can lead to loss of lean muscle mass alongside fat loss, which is a consideration for long-term health.
What We Don't Know Yet
Several important questions remain unanswered:
- Long-term safety beyond a few years is still being studied for both drugs. We don't have definitive data on what happens when people take these medications for a decade or more.
- We don't yet know if tirzepatide's greater weight loss translates to greater heart protection. It's plausible, but unproven until the cardiovascular outcome trials report.
- Individual responses vary widely. The averages from trials don't tell you exactly how you'll respond.
Practical Takeaways
If maximum weight loss is your primary goal and you tolerate the medication well, Zepbound typically produces more weight loss than Wegovy based on trial data.
If you have established heart disease or are at high cardiovascular risk and want proven protection against heart attacks and strokes, Wegovy currently has the stronger evidence supporting those outcomes.
Either way, expect GI side effects during dose escalation. Both drugs work similarly in this regard.
This decision belongs in a conversation with your prescriber. Your medical history, other conditions, mental health background, insurance coverage, and personal priorities all factor in. Neither drug is universally "better" for everyone.
The choice isn't permanent. Some people try one medication, experience intolerable side effects, and switch. The research suggests these are both effective options for significant weight loss, just with different strengths based on current evidence.
